ๆญฃๅœจๅŠ ่ฝฝ่ง†้ข‘...

่ง†้ข‘ๅŠ ่ฝฝๅคฑ่ดฅ

่ฟ”ๅ›ž้ฆ–้กต

๐Ž๐Ÿ๐Ÿ-๐“๐š๐ซ๐ ๐ž๐ญ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ: BridgeBio Pharma Founder & CEO Neil Kumar and Roivant Sciences CEO Matt Gline discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term. $BBIO $ROIV Watch the full episode:

BiotechTV's profile picture

BiotechTV

12,040 subscribers

11,893 ๆฌก่ง‚็œ‹ โ€ข 5 ไธชๆœˆๅ‰ โ€ขvia X (Twitter)

LIVE

Anya Rossiโ€ข Live Now

Private livecam show

1 ๆก่ฏ„่ฎบ

J M ็š„ๅคดๅƒ
J M4 ไธชๆœˆๅ‰

@BridgeBioPharma @Roivant @gline I think the targeted effect is glenn, hiding the a b 101 forty milligram cohort results

็›ธๅ…ณ่ง†้ข‘

๐Ž๐Ÿ๐Ÿ-๐“๐š๐ซ๐ ๐ž๐ญ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ: Perceptive Advisors' Joe Edelman discusses with Roivant Sciences CEO Matt Gline how biotech investing has changed over his extensive career, and his philosophy on running an investment firm. Watch the full episode:
3:18

๐Ž๐Ÿ๐Ÿ-๐“๐š๐ซ๐ ๐ž๐ญ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ: Perceptive Advisors' Joe Edelman discusses with Roivant Sciences CEO Matt Gline how biotech investing has changed over his extensive career, and his philosophy on running an investment firm. Watch the full episode:

BiotechTV

17,323 ๆฌก่ง‚็œ‹ โ€ข 3 ไธชๆœˆๅ‰

๐Ž๐Ÿ๐Ÿ-๐“๐š๐ซ๐ ๐ž๐ญ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ: Matt Gline speaks with Avoro Capital's Behzad Aghazadeh about the hot button issues that have been striking the biotech sector. Full video:
7:13

๐Ž๐Ÿ๐Ÿ-๐“๐š๐ซ๐ ๐ž๐ญ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ: Matt Gline speaks with Avoro Capital's Behzad Aghazadeh about the hot button issues that have been striking the biotech sector. Full video:

BiotechTV

21,055 ๆฌก่ง‚็œ‹ โ€ข 1 ๅนดๅ‰

๐“๐จ๐ฆ๐จ๐ซ๐ซ๐จ๐ฐ: Tune in tomorrow morning for a new episode of Off-Target Effects with Roivant Sciences CEO Matt Gline. Matt's next guest needs no introduction and is one of the most experienced investors in biotech, Perceptive Advisors' CEO and Portfolio Manager Joe Edelman!
0:48

๐“๐จ๐ฆ๐จ๐ซ๐ซ๐จ๐ฐ: Tune in tomorrow morning for a new episode of Off-Target Effects with Roivant Sciences CEO Matt Gline. Matt's next guest needs no introduction and is one of the most experienced investors in biotech, Perceptive Advisors' CEO and Portfolio Manager Joe Edelman!

BiotechTV

20,898 ๆฌก่ง‚็œ‹ โ€ข 3 ไธชๆœˆๅ‰

๐Ž๐Ÿ๐Ÿ-๐“๐š๐ซ๐ ๐ž๐ญ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ: John Maraganore ๐Ÿ‡บ๐Ÿ‡ธ๐Ÿ‡ฌ๐Ÿ‡ท๐Ÿ‡บ๐Ÿ‡ฆ has been a champion of innovation throughout his career. He and Matt Gline discuss the road to success at Alnylam Pharmaceuticals, today's environment, and keeping the U.S. on top. Watch the episode:
0:33

๐Ž๐Ÿ๐Ÿ-๐“๐š๐ซ๐ ๐ž๐ญ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ: John Maraganore ๐Ÿ‡บ๐Ÿ‡ธ๐Ÿ‡ฌ๐Ÿ‡ท๐Ÿ‡บ๐Ÿ‡ฆ has been a champion of innovation throughout his career. He and Matt Gline discuss the road to success at Alnylam Pharmaceuticals, today's environment, and keeping the U.S. on top. Watch the episode:

BiotechTV

20,496 ๆฌก่ง‚็œ‹ โ€ข 6 ไธชๆœˆๅ‰

Analyst Thursdays: TDCowenResearch's Tyler Van Buren discusses recent news from Acelyrin and Rocket Pharma, and comments on Moderna, BridgeBio, Iovance, and Allogene. $SLRN $RCKT $MRNA $BBIO $IOVA $ALLO Full video:
1:54

Analyst Thursdays: TDCowenResearch's Tyler Van Buren discusses recent news from Acelyrin and Rocket Pharma, and comments on Moderna, BridgeBio, Iovance, and Allogene. $SLRN $RCKT $MRNA $BBIO $IOVA $ALLO Full video:

BiotechTV

40,735 ๆฌก่ง‚็œ‹ โ€ข 3 ๅนดๅ‰

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Meet some of the incredible Female Biotech CEO leaders of the Biotech CEO Sisterhood!
1:37

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Meet some of the incredible Female Biotech CEO leaders of the Biotech CEO Sisterhood!

BiotechTV

12,358 ๆฌก่ง‚็œ‹ โ€ข 8 ไธชๆœˆๅ‰

Group CEO Mohit Kamboj Bharatiya spoke about the evolving business landscape and the need to stay prepared, aligned, and focused on sustainable growth. #aspectglobal #business #akshakamboj
18:52

Group CEO Mohit Kamboj Bharatiya spoke about the evolving business landscape and the need to stay prepared, aligned, and focused on sustainable growth. #aspectglobal #business #akshakamboj

Aspect

62,192 ๆฌก่ง‚็œ‹ โ€ข 5 ไธชๆœˆๅ‰

๐๐ž๐ฐ ๐’๐ก๐จ๐ฐ ๐€๐ง๐ง๐จ๐ฎ๐ง๐œ๐ž๐ฆ๐ž๐ง๐ญ: Today BiotechTV is excited to announce our newest regular show - Off-Target Effects with Matt Gline. Matt will share his perspective on news, and interview other biotech leaders. Visit the show's dedicated page:
2:56

๐๐ž๐ฐ ๐’๐ก๐จ๐ฐ ๐€๐ง๐ง๐จ๐ฎ๐ง๐œ๐ž๐ฆ๐ž๐ง๐ญ: Today BiotechTV is excited to announce our newest regular show - Off-Target Effects with Matt Gline. Matt will share his perspective on news, and interview other biotech leaders. Visit the show's dedicated page:

BiotechTV

37,175 ๆฌก่ง‚็œ‹ โ€ข 1 ๅนดๅ‰

WATCH: RMB CEO Alice Uwase says Rwanda does not need DR Congoโ€™s minerals to develop, calling for value addition and a sustainable strategy to position the country as a minerals business hub.
0:29

WATCH: RMB CEO Alice Uwase says Rwanda does not need DR Congoโ€™s minerals to develop, calling for value addition and a sustainable strategy to position the country as a minerals business hub.

The New Times (Rwanda)

22,074 ๆฌก่ง‚็œ‹ โ€ข 8 ไธชๆœˆๅ‰

Our President and CEO, Justin Hotard and Jensen Huang, Founder and CEO, NVIDIA, spoke with Bloomberg TV earlier today about the partnership and importance of bringing AI to networks and networks to AI. Watch the full interview: #NVIDIAGTC #Nokia
1:19

Our President and CEO, Justin Hotard and Jensen Huang, Founder and CEO, NVIDIA, spoke with Bloomberg TV earlier today about the partnership and importance of bringing AI to networks and networks to AI. Watch the full interview: #NVIDIAGTC #Nokia

Nokia

40,831 ๆฌก่ง‚็œ‹ โ€ข 11 ไธชๆœˆๅ‰

Arena Conversations: Peter Gostev sat down with Matt โ€“ Trigger.dev, founder and CEO of Trigger.dev, to discuss building infrastructure for long-running agents, including retries, API reliability, and why customers are switching frontier models faster than ever. Watch the full episode at the link below.
1:00

Arena Conversations: Peter Gostev sat down with Matt โ€“ Trigger.dev, founder and CEO of Trigger.dev, to discuss building infrastructure for long-running agents, including retries, API reliability, and why customers are switching frontier models faster than ever. Watch the full episode at the link below.

Arena.ai

16,619 ๆฌก่ง‚็œ‹ โ€ข 26 ๅคฉๅ‰

๐๐ซ๐ž๐š๐ค๐ข๐ง๐  ๐Œ&๐€ ๐๐ž๐ฐ๐ฌ: Lilly is acquiring Crossbridgebio, a Texas biotech developing dual payload antibody-drug conjugates, for up to $300M. Co-Founder & CEO Michael Torres tells us.
4:50

๐๐ซ๐ž๐š๐ค๐ข๐ง๐  ๐Œ&๐€ ๐๐ž๐ฐ๐ฌ: Lilly is acquiring Crossbridgebio, a Texas biotech developing dual payload antibody-drug conjugates, for up to $300M. Co-Founder & CEO Michael Torres tells us.

BiotechTV

20,285 ๆฌก่ง‚็œ‹ โ€ข 5 ไธชๆœˆๅ‰

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: With three approved products and filings for more over the near term, Axsome Therapeutics's CEO describes the scale and reach this company is building in the CNS space. $AXSM Full video:
3:36

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: With three approved products and filings for more over the near term, Axsome Therapeutics's CEO describes the scale and reach this company is building in the CNS space. $AXSM Full video:

BiotechTV

20,956 ๆฌก่ง‚็œ‹ โ€ข 1 ๅนดๅ‰

In our newest Tech Talks episode, Roblox CEO & Founder David Baszucki, Kiran Bhat, and Alberto Hojel discuss what makes Roblox's 3D-native foundation model different from your standard video model, allowing creators to build functional objects and worlds from prompts. Watch the full episode on YouTube now.
0:54

In our newest Tech Talks episode, Roblox CEO & Founder David Baszucki, Kiran Bhat, and Alberto Hojel discuss what makes Roblox's 3D-native foundation model different from your standard video model, allowing creators to build functional objects and worlds from prompts. Watch the full episode on YouTube now.

Roblox

127,974 ๆฌก่ง‚็œ‹ โ€ข 6 ไธชๆœˆๅ‰

Millions of people living with #geneticdiseases are still waiting for treatments. At BridgeBio, our mission is to put patients first and push the boundaries of science to meet those needs. CEO Neil Kumar Ph.D., joined Deirdre Bolton at the Milken Institute Global Conference to highlight the urgency and opportunity in addressing rare and underserved conditions. Listen to the full video here:
0:43

Millions of people living with #geneticdiseases are still waiting for treatments. At BridgeBio, our mission is to put patients first and push the boundaries of science to meet those needs. CEO Neil Kumar Ph.D., joined Deirdre Bolton at the Milken Institute Global Conference to highlight the urgency and opportunity in addressing rare and underserved conditions. Listen to the full video here:

BridgeBio Pharma

117,615 ๆฌก่ง‚็œ‹ โ€ข 1 ๅนดๅ‰

Our CEO and co-founder Evan Spiegel sat down with Steven Bartlett in the latest episode of The Diary of a CEO. ๐Ÿ“–๐ŸŽค Watch:
1:22

Our CEO and co-founder Evan Spiegel sat down with Steven Bartlett in the latest episode of The Diary of a CEO. ๐Ÿ“–๐ŸŽค Watch:

Snapchat

54,417 ๆฌก่ง‚็œ‹ โ€ข 1 ๅนดๅ‰

Highlights from COP29 Azerbaijan 19 November - Biotech & Pharma Report Launch Biotech & Pharma Report Launch โ€“ Unveiling the Carbon Impact Report of Biotech and Pharma Join My Green Lab for the release of the 2024 Carbon Impact of Biotech & Pharma Report. Taking place during COP 29, this special, virtual event will explore pivotal developments from Baku, spotlight findings from My Green Labโ€™s updated โ€˜Carbon Impact Report of Biotech and Pharmaโ€™ report, and celebrate the milestones achieved through their Converge Supplier Initiative. In this 60-minute session, you will hear from industry leaders in sustainable science and gain insights from My Green Lab CEO, James Connelly, on how they are propelling the Pharma and Medtech sector to achieve UN-backed Race to Zero Breakthrough Outcome, with a goal to certify 95% of their labs with the My Green Lab Certification at the highest โ€˜Greenโ€™ level by 2030. Speakers: Devin Carsdale, Sustainable Procurement Lead, Bristol Myers Squibb James Connelly, CEO, My Green Lab Larry Lawrence, VP, Sustainable Finance, ICE Organizers: We Don't Have Time My Green Lab Watch the full session here: or Follow all sessions from COP29 on:
3:36

Highlights from COP29 Azerbaijan 19 November - Biotech & Pharma Report Launch Biotech & Pharma Report Launch โ€“ Unveiling the Carbon Impact Report of Biotech and Pharma Join My Green Lab for the release of the 2024 Carbon Impact of Biotech & Pharma Report. Taking place during COP 29, this special, virtual event will explore pivotal developments from Baku, spotlight findings from My Green Labโ€™s updated โ€˜Carbon Impact Report of Biotech and Pharmaโ€™ report, and celebrate the milestones achieved through their Converge Supplier Initiative. In this 60-minute session, you will hear from industry leaders in sustainable science and gain insights from My Green Lab CEO, James Connelly, on how they are propelling the Pharma and Medtech sector to achieve UN-backed Race to Zero Breakthrough Outcome, with a goal to certify 95% of their labs with the My Green Lab Certification at the highest โ€˜Greenโ€™ level by 2030. Speakers: Devin Carsdale, Sustainable Procurement Lead, Bristol Myers Squibb James Connelly, CEO, My Green Lab Larry Lawrence, VP, Sustainable Finance, ICE Organizers: We Don't Have Time My Green Lab Watch the full session here: or Follow all sessions from COP29 on:

We Don't Have Time

125,818 ๆฌก่ง‚็œ‹ โ€ข 1 ๅนดๅ‰